The Effects of GLA (5 mcg) on Human Volunteers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01864876|
Recruitment Status : Completed
First Posted : May 30, 2013
Last Update Posted : February 26, 2014
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Healthy Volunteers||Biological: GLA-AF Biological: GLA-SE Biological: EM060G (SE)||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||17 participants|
|Intervention Model:||Single Group Assignment|
|Primary Purpose:||Basic Science|
|Official Title:||A Randomized, Single-Blinded Phase 1 Study to Evaluate the Safety and Immunogenicity of a Single Administration of 5 mcg GLA in Healthy Volunteers|
|Study Start Date :||September 2012|
|Actual Primary Completion Date :||December 2013|
|Actual Study Completion Date :||December 2013|
5 mcg GLA-AF given as one subcutaneous injection.
Glucopyranosyl Lipid A (GLA) in an aqueous formulation (AF).
5 mcg GLA-SE given as one intramuscular injection.
Glucopyranosyl Lipid A (GLA) in a stable oil-in-water emulsion (SE).
Experimental: EM060G (SE)
EM060G (SE) given as one intramuscular injection.
Biological: EM060G (SE)
The same stable oil-in-water emulsion (SE), but without GLA.
- Safety [ Time Frame: 1 year ]
Local reactogenicity events and systemic reactogenicity events will be monitored for 28 days post injection.
- Local reactogenicity events include tenderness, erythema, skin discoloration, edema, vesicle formation or ulceration, induration, pruritus, formation of a crust or scab, or other.
- Systemic reactogenicity events include fever, chills, headache, nausea, vomiting, malaise, myalgia, arthralgia, and rash.
Long term safety will be monitored by follow-up phone calls at 3 months, 6 months, and 1 year post injection.
- Immunogenicity [ Time Frame: 28 days ]Describe the global immune response by measuring systemic cytokines, chemokines and global gene regulation. Investigate the effects of GLA on the peripheral blood immune cells including monocytes and dendritic cells.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 50 Years (Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
- Healthy adult males and females, as assessed by a medical history, physical exam,and laboratory tests;
- Age of at least 18 years of age on the day of screening and no greater than 50 years at time of administration;
- Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study (screening plus 4 weeks);
- Willing to undergo HIV testing and counseling and receive HIV test results;
- If a female of child bearing potential, must be willing to use two effective methods of contraception (combined oral contraceptive pill; injectable contraceptive; diaphragm; Intra Uterine Device (IUD); condoms; anatomical sterility in self or partner) until 6 weeks after study drug administration. If a sexually active male, must be willing to use two effective methods of contraception (such as condoms, anatomical sterility) from screening until 6 weeks after study drug administration (same as above) and will be advised not to get his partner(s) pregnant during this time.
- Positive for hepatitis B surface antigen, positive for hepatitis C antibodies, or active syphilis infection based on clinical evaluation;
- Confirmed HIV-1 or HIV-2 infection;
- Any clinically significant abnormality on medical history or physical examination including history of immunodeficiency or autoimmune disease;
- Any use of systemic corticosteroids immunosuppressive anticancer medications;
- Any clinically significant acute or chronic medical condition requiring care of a physician (e.g., diabetes, coronary artery disease, rheumatologic illness, malignancy, substance abuse) that in the opinion of the investigator would preclude participation;
- Any laboratory value outside of reference range other than CRP, with the exception of any non-clinically significant Grade I elevations of liver function tests (AST, ALT, direct/total bilirubin), electrolytes (Na, K, Cl, CO2), CBC, urinalysis as determined by the Principal Investigator or his designee.
- Within the 12 months prior to enrollment, the subject self reports excessive daily alcohol use, frequent binge drinking or chronic marijuana abuse (defined as greater than 2 times a week) or any other use of illicit drugs;
- If female, pregnant, planning a pregnancy during the trial period, or lactating;
- Receipt of a live attenuated vaccine within 30 days or other vaccine within 14 days prior to study drug;
- Prior receipt of GLA in another research study;
- Participation in another clinical study of an investigational product currently or within past 16 weeks, or expected participation during this study;
- In the opinion of the investigator, unlikely to comply with protocol due to medical, social or psychiatric reasons;
- Allergy to eggs
- A glomerular filtration rate that is less than 60 mL/min/1.73 m2 as calculated by study team based on laboratory creatinine values.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01864876
|United States, New York|
|New York, New York, United States, 10065|
|Study Director:||Franco Piazza, MD, MPH||Access to Advanced Health Institute (AAHI)|
|Responsible Party:||Access to Advanced Health Institute (AAHI)|
|Other Study ID Numbers:||
|First Posted:||May 30, 2013 Key Record Dates|
|Last Update Posted:||February 26, 2014|
|Last Verified:||February 2014|